PTC Therapeutics, Inc.
General ticker "PTCT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.0B (TTM average)
PTC Therapeutics, Inc. follows the US Stock Market performance with the rate: 52.4%.
Estimated limits based on current volatility of 3.7%: low 75.38$, high 81.12$
Factors to consider:
- Total employees count: 995 as of 2023
- US accounted for 25.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Manufacturing disruptions, Geopolitical risks, Marketing effectiveness, Reimbursement risks
- Current price 14.9% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [28.18$, 67.76$]
- 2025-12-31 to 2026-12-31 estimated range: [22.80$, 56.47$]
Financial Metrics affecting the PTCT estimates:
- Negative: with PPE of -11.4 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -3.08 <= 0.33
- Positive: Investing cash flow per share per price, % of 1.26 > -0.66
- Negative: negative Net income
- Positive: Inventory ratio change, % of -0.94 <= -0.75
Short-term PTCT quotes
Long-term PTCT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $724.70MM | $937.82MM | $810.50MM |
| Operating Expenses | $1,172.11MM | $1,377.32MM | $1,113.08MM |
| Operating Income | $-447.41MM | $-439.50MM | $-302.57MM |
| Non-Operating Income | $-140.08MM | $-256.61MM | $-60.55MM |
| Interest Expense | $90.87MM | $129.18MM | $166.99MM |
| R&D Expense | $651.50MM | $666.56MM | $534.48MM |
| Income(Loss) | $-587.49MM | $-696.11MM | $-363.12MM |
| Taxes | $-28.47MM | $-69.51MM | $0.18MM |
| Profit(Loss)* | $-559.02MM | $-626.60MM | $-363.30MM |
| Stockholders Equity | $-347.09MM | $-818.55MM | $-1,098.07MM |
| Inventory | $21.81MM | $30.58MM | $23.19MM |
| Assets | $1,705.62MM | $1,895.70MM | $1,705.02MM |
| Operating Cash Flow | $-356.65MM | $-158.42MM | $-107.69MM |
| Capital expenditure | $152.46MM | $120.62MM | $74.25MM |
| Investing Cash Flow | $290.18MM | $-176.74MM | $44.18MM |
| Financing Cash Flow | $167.95MM | $646.40MM | $255.87MM |
| Earnings Per Share** | $-7.79 | $-8.37 | $-4.73 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.